Insilico Medicine, a clinical-stage generative AI-powered drug discovery company, today announced its participation in the upcoming PFF Summit, taking place November 13-15, 2025, in Chicago, IL. At the event, the Insilico Medicine team will be present at Booth #28, where they will showcase their latest AI-driven clinical research through three scientific posters.
- Poster #1: Rentosertib (INS018_055), A Novel AI-Designed TNIK Inhibitor, Improves Lung Function in Patients with Idiopathic Pulmonary Fibrosis: Results From a Randomized, Placebo-Controlled Phase 2a Study.
- Poster #2: Antifibrotic and Anti-inflammatory Signatures in Idiopathic Pulmonary Fibrosis Patients Treated With Rentosertib (INS018_055), an AI-Discovered TNIK Inhibitor, in a 12-Week Phase 2a Study.
- Poster #3: Phase 2a Cohort Characteristics and Lung Imaging Indicate Correlates of Response to ISM001-055 (Rentosertib) in Patients With Idiopathic Pulmonary Fibrosis.
As part of the world’s largest gathering for pulmonary fibrosis (PF) and interstitial lung disease (ILD) research and education, Insilico will highlight significant advances achieved with Rentosertib (INS018_055/ISM001-055), a novel AI-designed TNIK inhibitor. Rentosertib demonstrated a mean improvement in lung function as measured by FVC, and biomarker analysis showed antifibrotic and anti-inflammatory effects in patients with idiopathic pulmonary fibrosis (IPF) in randomized, placebo-controlled Phase 2a studies, including the GENESIS-IPF trial. Results over 12 weeks of treatment revealed promising therapeutic outcomes, with cohort analysis and lung imaging further identifying potential markers of patient response, supporting the drug’s potential for IPF management.
Since pioneering next-generation AI in drug discovery, Insilico Medicine has built an extensive therapeutic portfolio across high-demand areas, rapidly advancing its internal R&D pipeline and setting a new standard for efficiency. While traditional early-stage drug discovery can take 2.5 to 4 years, Insilico has nominated 20 preclinical candidates at an average pace of just 12 to 18 months per program, synthesizing and testing only 60 to 200 molecules each.
Since founding in 2014, Insilico has published over 200 peer-reviewed papers. Leveraging sustained scientific breakthroughs at the intersection of biotechnology, artificial intelligence, and automation, Insilico ranked Top 100 global corporate institutions in Nature Index's "2025 Research Leaders: global corporate institutions for biological sciences and natural sciences publications".
References
[1] Ren, F., Aliper, A., Chen, J. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02143-0
[2] Xu, Z., Ren, F., Wang, P. et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nat Med 31, 2602–2610 (2025). https://doi.org/10.1038/s41591-025-03743-2
About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, visit www.insilico.com.